S-1: Cyclacel Pharmaceuticals Files for Potential Resale of Over 170 Million Shares

Cyclacel Pharmaceuticals has filed a registration statement for the potential resale of over 170 million shares of its common stock by selling shareholders.

Summary

• Cyclacel Pharmaceuticals has filed a Form S-1 registration statement with the SEC.
• The filing covers the potential resale of up to 170,026,676 shares of common stock by selling shareholders.
• This includes shares underlying prepaid warrants held by Armistice Capital Master Fund Ltd., shares underlying Series E preferred stock held by accredited investors, shares held by Helena Special Opportunities 1 Ltd., and shares held by the company's CEO, Datuk Dr. Doris Wong Sing Ee.
• The company will not receive any proceeds from the sale of these shares.
• As of April 23, 2025, Cyclacel had 246,357,569 shares of common stock outstanding.
• The last quoted sale price for Cyclacel's common stock on The Nasdaq Capital Market on April 23, 2025, was $0.23 per share.
• The company is classified as a smaller reporting company and is subject to a Mandatory Panel Monitor for one year from February 25, 2025.

Sentiment

Score: 4

Explanation: The document is largely factual, but the inclusion of risk factors and going concern warnings tempers any positive outlook. The potential for dilution and the company's financial instability contribute to a negative sentiment.

Risks

• The document highlights several risk factors, including risks associated with the development and commercialization of drug candidates, the company's financial condition, intellectual property, and securities regulations.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company may need to raise additional capital in the near future, which may not be available on reasonable terms.
• The company faces intense competition and may not be able to compete successfully.
• Failure to comply with Nasdaq Capital Market listing requirements could result in delisting.
• The future sale of common and convertible preferred stock could negatively affect the stock price and cause dilution.

Future Outlook

The company anticipates that its cash and cash equivalents as of December 31, 2024, along with private placement proceeds from Q1 2025, will allow it to meet liquidity requirements into the second quarter of 2025, but there is no guarantee of raising additional funds.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors.

Management Changes

Stakeholder Impact

• The potential resale of a large number of shares could create downward pressure on the market price of the common stock, impacting current shareholders.
• The company's ability to raise additional capital and continue operations is uncertain, which could affect employees and other stakeholders.

Next Steps

• The Selling Shareholders may offer the shares from time to time through public or private transactions.
• The Company agreed to call a meeting of stockholders for purposes of soliciting approval of the issuance of all the shares of common stock upon conversion of the Series E Preferred Stock pursuant to the terms of the Purchase Agreement and an amendment to the Certificate of Designations for the Series E Preferred Stock (the Series E Preferred Certificate of Designations) in order to remove the Series E Ownership Limitation.
• The Company agreed to call a meeting of stockholders for purposes of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the Certificate), to increase the number of authorized shares of common stock from 250,000,000 shares to 600,000,000 shares.

Key Dates

Keywords

common stock, selling shareholders, registration statement, preferred stock, Cyclacel Pharmaceuticals, shares, warrants, resale, private placement, securities